耐信是哪个国家的？

(Esomeprazole) is a new anti-pathogenic agent. On July 30, 2020, AstraZeneca announced that the China National Medical Products Administration (NMPA) officially approved Nexium (esomeprazole sodium) injection for the prevention of stress ulcer bleeding in severe patients. Today let’s take a closer look at which country Nexium is from?

Nexium (esomeprazole) currently on the drug market is mainly produced by AstraZeneca Pharmaceutical Co., Ltd. Nexium is used for the treatment of gastroesophageal reflux disease (GERD), including erosive reflux esophagitis, long-term maintenance treatment to prevent recurrence of cured esophagitis patients, and symptom control of gastroesophageal reflux disease (GERD). And combined with appropriate antimicrobial therapy, it can eradicate Helicobacter pylori, heal duodenal ulcers associated with Helicobacter pylori infection, and prevent the recurrence of peptic ulcers associated with Helicobacter pylori infection.

Nexium (esomeprazole) is available in oral and injection forms. For gastric and duodenal ulcers: 20 mg each time, taken once in the morning. The treatment course for duodenal ulcer is usually 2 to 4 weeks, and the treatment course for gastric ulcer is 4 to 8 weeks. For those with refractory ulcers, 20 mg twice a day or 40 mg once a day can be used. Although oral administration of Nexium can achieve good clinical results, in some patients, such as patients with dysphagia, vomiting, acute upper gastrointestinal bleeding, and patients recovering from major surgery, when used to treat peptic ulcer bleeding, intravenous injection of 40 mg can be given, once every 12 hours, for 3 days. The first dose may be doubled. For patients with severe bleeding, intravenous infusion of 80 mg can be used for the first dose, and then maintained at 8 mg per hour until the bleeding stops.

Nexium (esomeprazole) has been marketed in many countries. In 2000, Nexium's oral preparation was first launched in Sweden. In 2001, it was approved by the FDA to be marketed in the United States under the trade name Nexium. In 2003, Nexium sodium for injection developed by AstraZeneca was first launched in Sweden and was approved for marketing in the United States in 2005.

Nexium (esomeprazole) is a weak base that is concentrated in the high-acid environment of parietal cell acid secretion microtubules and converted into an active form, inhibiting both basal and stimulated gastric acid secretion.

The above is the content of the (esomeprazole) manufacturer, I hope it can help you!

Recommended related hot articles: /newsDetail/75679.html